Posted by Michael Wonder on 16 Dec 2022
Dupixent (dupilumab) recommended for EU approval by the CHMP for the treatment of eosinophilic oesophagitis
16 December 2022 - If approved, Dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with eosinophilic oesophagitis in the European Union.
The EMA’s CHMP has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the European Union to treat adults and adolescents with eosinophilic oesophagitis.
